Ipilimumab Versus Placebo After <br />Complete Resection of Stage III Melanoma: <br />Initial Efficacy and Safety Results from the EORTC 18071 Phase III Trial
Presented By Alexander Eggermont at 2014 ASCO Annual Meeting
Slide 2
Presented By Alexander Eggermont at 2014 ASCO Annual Meeting
Slide 3
Presented By Alexander Eggermont at 2014 ASCO Annual Meeting
Immune Checkpoint Inhibitor Ipilimumab
Presented By Alexander Eggermont at 2014 ASCO Annual Meeting
EORTC 18071/CA184-029: Study Design
Presented By Alexander Eggermont at 2014 ASCO Annual Meeting
Key Eligibility Criteria
Presented By Alexander Eggermont at 2014 ASCO Annual Meeting
Slide 7
Presented By Alexander Eggermont at 2014 ASCO Annual Meeting
Baseline Patient Characteristics
Presented By Alexander Eggermont at 2014 ASCO Annual Meeting
Primary Endpoint: Recurrence-free Survival (IRC)
Presented By Alexander Eggermont at 2014 ASCO Annual Meeting
Recurrence-free Survival: Prespecified Subgroups
Presented By Alexander Eggermont at 2014 ASCO Annual Meeting
Slide 11
Presented By Alexander Eggermont at 2014 ASCO Annual Meeting
Slide 12
Presented By Alexander Eggermont at 2014 ASCO Annual Meeting
Time to Onset of Grade 2-5 irAEs
Presented By Alexander Eggermont at 2014 ASCO Annual Meeting
Slide 14
Presented By Alexander Eggermont at 2014 ASCO Annual Meeting
Slide 15
Presented By Alexander Eggermont at 2014 ASCO Annual Meeting
Subgroup Analyses of RFS: Microscopic (N1) vs Clinically Palpable (N2) Lymph Nodes
Presented By Alexander Eggermont at 2014 ASCO Annual Meeting
Summary/Conclusions
Presented By Alexander Eggermont at 2014 ASCO Annual Meeting
Acknowledgments
Presented By Alexander Eggermont at 2014 ASCO Annual Meeting
